Publish in this journal
Journal Information
Vol. 69. Issue 7.
Pages 715 (July 2016)
Vol. 69. Issue 7.
Pages 715 (July 2016)
Letter to the Editor
Full text access
About the Micra Transcatheter Pacing System
Acerca del sistema de marcapasos transcatéter Micra
Visits
...
Ángel Morales Martínez de Tejada
Corresponding author
hispano0@yahoo.es

Corresponding author:
, Javier Elduayen Gragera
Servicio de Cardiología, Hospital Regional Universitario Infanta Cristina, Badajoz, Spain
Related content
Marta Pachón, Alberto Puchol, Finn Akerström, Luis Rodríguez-Padial, Miguel A. Arias
Rev Esp Cardiol. 2016;69:71610.1016/j.rec.2016.04.016
Marta Pachón, Miguel A. Arias
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

We read in detail the interesting article by Pachón et al1 on implantation of the Micra transcatheter pacing system. Due to its characteristics, this model could undoubtedly be extremely useful in certain patients.2 However, it has certain limitations. Regarding the series of 10 patients presented, we would like to make several observations:

Of the 10 patients, 2 (patients 5 and 8) were in sinus rhythm prior to implantation; usually, implantation with a DDD pacemaker would be indicated in this situation. With right ventricular pacing only, atrial fibrillation is likely to develop in the medium- to long-term. This is particularly likely in the case of the patient with a pacing percentage of more than 20%, as measured after implantation. Aside from the clinical deterioration that could result from the loss of atrioventricular synchrony, the patient would require anticoagulation. In the case of the other patient with a baseline sinus rhythm, the R wave amplitude was only 4.7mV after the first implantation, whereas the manufacturer's recommendation3 is ≥ 5 mV.

Patients 1 and 2 have a pacing threshold of 0.24ms higher than the manufacturer's recommendation in the technical specifications3 (1mV).

Regarding the patient with a QRS of 140ms and erratic control of atrial fibrillation (patient 4), it is possible that at follow-up she will require a change to cardiac resynchronization therapy (provided the clinical profile indicates and allows this). With this system, such a change would not be feasible and could even hamper implantation of new electro-catheters in the right ventricle.

In light of these points, this seems to be an interesting and novel pacing system, but with some limitations, especially for patients who are in sinus rhythm or who require a change to cardiac resynchronization at follow-up.

References
[1]
M. Pachón, A. Puchol, F. Akerström, L. Rodríguez-Padial, M.A. Arias.
Implante de marcapasos sin cables transcatéter Micra: experiencia inicial en un centro español.
Rev Esp Cardiol., 69 (2016), pp. 346-349
[2]
M.A. Miller, P. Neuzil, S.R. Dukkipati, V.Y. Reddy.
Leadless cardiac pacemakers: back to the future.
J Am Coll Cardiol., 66 (2015), pp. 1179-1189
[3]
D. Reynolds, G.Z. Duray, R. Omar, K. Soejima, P. Neuzil, S. Zhang, et al.
A leadless intracardiac transcatheter pacing system.
N Engl J Med., 374 (2016), pp. 533-541
Copyright © 2016. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?